Your browser doesn't support javascript.
loading
Temporal genomic analysis of melanoma rejection identifies regulators of tumor immune evasion.
Cohen Shvefel, Sapir; Pai, Joy A; Cao, Yingying; Pal, Lipika R; Levy, Ronen; Yao, Winnie; Cheng, Kuoyuan; Zemanek, Marie; Bartok, Osnat; Weller, Chen; Yin, Yajie; Du, Peter P; Yakubovich, Elizabeta; Orr, Irit; Ben-Dor, Shifra; Oren, Roni; Fellus-Alyagor, Liat; Golani, Ofra; Goliand, Inna; Ranmar, Dean; Savchenko, Ilya; Ketrarou, Nadav; Schäffer, Alejandro A; Ruppin, Eytan; Satpathy, Ansuman T; Samuels, Yardena.
Afiliação
  • Cohen Shvefel S; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Pai JA; Department of Pathology, Stanford University, Stanford, CA, USA.
  • Cao Y; Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Pal LR; Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Levy R; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Yao W; Department of Pathology, Stanford University, Stanford, CA, USA.
  • Cheng K; Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Zemanek M; MSD R&D (China) Co., Ltd.
  • Bartok O; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Weller C; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Yin Y; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Du PP; Department of Pathology, Stanford University, Stanford, CA, USA.
  • Yakubovich E; Department of Pathology, Stanford University, Stanford, CA, USA.
  • Orr I; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Ben-Dor S; Bioinformatics Unit, Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel.
  • Oren R; Bioinformatics Unit, Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel.
  • Fellus-Alyagor L; Department of Veterinary Resources, Weizmann Institute of Science, Rehovot, Israel.
  • Golani O; Department of Veterinary Resources, Weizmann Institute of Science, Rehovot, Israel.
  • Goliand I; Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel.
  • Ranmar D; Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel.
  • Savchenko I; Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel.
  • Ketrarou N; Department of Veterinary Resources, Weizmann Institute of Science, Rehovot, Israel.
  • Schäffer AA; Department of Veterinary Resources, Weizmann Institute of Science, Rehovot, Israel.
  • Ruppin E; Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Satpathy AT; Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Samuels Y; Department of Pathology, Stanford University, Stanford, CA, USA.
bioRxiv ; 2023 Nov 29.
Article em En | MEDLINE | ID: mdl-38077050
ABSTRACT
Decreased intra-tumor heterogeneity (ITH) correlates with increased patient survival and immunotherapy response. However, even highly homogenous tumors may display variability in their aggressiveness, and how immunologic-factors impinge on their aggressiveness remains understudied. Here we studied the mechanisms responsible for the immune-escape of murine tumors with low ITH. We compared the temporal growth of homogeneous, genetically-similar single-cell clones that are rejected vs. those that are not-rejected after transplantation in-vivo using single-cell RNA sequencing and immunophenotyping. Non-rejected clones showed high infiltration of tumor-associated-macrophages (TAMs), lower T-cell infiltration, and increased T-cell exhaustion compared to rejected clones. Comparative analysis of rejection-associated gene expression programs, combined with in-vivo CRISPR knockout screens of candidate mediators, identified Mif (macrophage migration inhibitory factor) as a regulator of immune rejection. Mif knockout led to smaller tumors and reversed non-rejection-associated immune composition, particularly, leading to the reduction of immunosuppressive macrophage infiltration. Finally, we validated these results in melanoma patient data.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article